Brisbane-based Intermune (NASDAQ: ITMN) said Shionogi's complaint alleges that Intermune broke an agreement between the companies by using some of Shionogi's proprietary information in a regulatory application with the European Medicines Agency and then failing to pay royalties on sales of the drug there.
Showing posts with label InterMune. Show all posts
Showing posts with label InterMune. Show all posts
Sunday, July 8, 2012
InterMune sued by partner Shionogi over Esbriet royalties in Europe
Intermune Inc. said it has been sued by Shionogi & Co. over royalties and license payments related to clinical trials of pirfenidone.
Tuesday, May 22, 2012
InterMune to divest Actimmune, focus deal cash on lung drug
The Brisbane company (NASDAQ: ITMN) said Monday that it has reached a definitive agreement with Vidara Therapeutics International Ltd. to sell the rights to Actimmune for $55 million and a two-year royalty stream. The cash will be funneled into registration and commercialization of Esbriet, InterMune’s treatment for the fatal lung-scarring disease idiopathic pulmonary fibrosis, and research and development.
Friday, December 16, 2011
InterMune to 'vigorously' fight German report on lung drug
InterMune Inc.’s drug to treat a deadly lung condition provides little benefit to patients, according to a German health organization.
The findings, published Thursday, could be a blow for Brisbane-based InterMune (NASDAQ: ITMN), which in February won approval in Europe for Esbriet as a treatment for the lung-scarring disease idiopathic pulmonary fibrosis. The company decided to launch Esbriet in Germany in the first half of 2012 and spread to other parts of the continent.
Saying it has “a number of important concerns” with the methodology used by the private Institute for Quality and Efficiency in Health Care, InterMune said it will “vigorously challenge” the assessment.
The findings, published Thursday, could be a blow for Brisbane-based InterMune (NASDAQ: ITMN), which in February won approval in Europe for Esbriet as a treatment for the lung-scarring disease idiopathic pulmonary fibrosis. The company decided to launch Esbriet in Germany in the first half of 2012 and spread to other parts of the continent.
Saying it has “a number of important concerns” with the methodology used by the private Institute for Quality and Efficiency in Health Care, InterMune said it will “vigorously challenge” the assessment.
Tuesday, September 13, 2011
InterMune prices stock, note offerings, seeks $222 million
InterMune Inc. will sell 4 million shares at $24 each and offer $135 million in convertible senior notes at 2.5 percent, the company said in a Securities and Exchange Commission filing late Tuesday.
The offerings, expected to close around Sept. 19, would net InterMune about $222 million, according to the Brisbane company (NASDAQ: ITMN).
The offerings, expected to close around Sept. 19, would net InterMune about $222 million, according to the Brisbane company (NASDAQ: ITMN).
Monday, September 12, 2011
InterMune could raise $200M in stock, notes deal
InterMune Inc. plans to raise $100 million through convertible notes and sell 4 million shares of common stock that could add another $100 million, the company said Monday.
The timing demonstrates some confidence by the Brisbane-based biotech drug developer (NASDAQ: ITMN) that its lung disease drug, Esbriet, can hit blockbuster status.
The timing demonstrates some confidence by the Brisbane-based biotech drug developer (NASDAQ: ITMN) that its lung disease drug, Esbriet, can hit blockbuster status.
InterMune set to launch lung drug in Germany
InterMune Inc. on Thursday will launch the first drug approved in Europe for use against a fatal lung-scarring disease.
The Brisbane company (NASDAQ: ITMN), which has struggled to win approval in the United States for Esbriet for patients with idiopathic pulmonary fibrosis, or IPF, will make the drug commercially available initially in Germany.
The Brisbane company (NASDAQ: ITMN), which has struggled to win approval in the United States for Esbriet for patients with idiopathic pulmonary fibrosis, or IPF, will make the drug commercially available initially in Germany.
Thursday, July 7, 2011
InterMune enrolls 1st patient in new lung disease trial
Jilted by the FDA in a previous attempt to win approval for its treatment for a fatal lung-scarring disease, InterMune Inc.said it has started a new Phase III study of its drug, called Esbriet.
The Brisbane company (NASDAQ: ITMN) said it enrolled the first patient in a roughly 500-patient trial designed to evaluate the safety and efficacy of Esbriet in people with mild to moderate idiopathic pulmonary fibrosis, or IPF.
The Brisbane company (NASDAQ: ITMN) said it enrolled the first patient in a roughly 500-patient trial designed to evaluate the safety and efficacy of Esbriet in people with mild to moderate idiopathic pulmonary fibrosis, or IPF.
Wednesday, May 11, 2011
Big InterMune shareholder weighs sale
If trackers of InterMune Inc. can’t get The Clash out of their heads, there’s good reason: Should they stay or should they go?
The issue is that investment firm Warburg Pincus may opt to sell all or a significant chunk of its holdings in InterMune Inc., the Brisbane company that late last month beat down rumors that it was being shopped.
InterMune (NASDAQ: ITMN) said in a Securities and Exchange Commission filing Tuesday that Warburg Pincus is “actively considering” selling its InterMune holdings as early as the end of next month.
The issue is that investment firm Warburg Pincus may opt to sell all or a significant chunk of its holdings in InterMune Inc., the Brisbane company that late last month beat down rumors that it was being shopped.
InterMune (NASDAQ: ITMN) said in a Securities and Exchange Commission filing Tuesday that Warburg Pincus is “actively considering” selling its InterMune holdings as early as the end of next month.
Thursday, April 28, 2011
InterMune leaves sale rumors unanswered
InterMune Inc. is not for sale — now stop asking.
That’s the takeaway from the Brisbane company’s (NASDAQ: ITMN) first-quarter recap conference call Thursday morning. But sources told Bloomberg and Dealreporter.com this week that the developer of the idiopathic pulmonary fibrosis drug Esbriet has been shopped around for a few weeks. Bloomberg said Goldman Sachs is managing the process.
That’s the takeaway from the Brisbane company’s (NASDAQ: ITMN) first-quarter recap conference call Thursday morning. But sources told Bloomberg and Dealreporter.com this week that the developer of the idiopathic pulmonary fibrosis drug Esbriet has been shopped around for a few weeks. Bloomberg said Goldman Sachs is managing the process.
Wednesday, April 27, 2011
Appeal for convicted former InterMune CEO will focus on 1st Amendment
The attorney for former InterMune Inc. CEO Scott Harkonen plans to pursue a First Amendment argument in appealing Harkonen’s conviction on a wire fraud charge.
Harkonen was sentenced last week to a $20,000 fine and six months of home confinement after a jury in September 2009 found him guilty of wire fraud. The center of the Department of Justice’s prosecution was an Aug. 28, 2002, press release that said the InterMune drug Actimmune in a Phase III trial reduced deaths by 70 percent in patients with mild to moderate idiopathic pulmonary fibrosis, a fatal lung-scarring disease.
But Mark Haddad of Sidley Austin LLP said Harkonen’s statement in the press release is protected speech because the CEO was drawing a scientific conclusion of data accurately reported in the press release. “To show conclusions of data is fundamental to the scientific process,” Haddad said.
Harkonen was sentenced last week to a $20,000 fine and six months of home confinement after a jury in September 2009 found him guilty of wire fraud. The center of the Department of Justice’s prosecution was an Aug. 28, 2002, press release that said the InterMune drug Actimmune in a Phase III trial reduced deaths by 70 percent in patients with mild to moderate idiopathic pulmonary fibrosis, a fatal lung-scarring disease.
But Mark Haddad of Sidley Austin LLP said Harkonen’s statement in the press release is protected speech because the CEO was drawing a scientific conclusion of data accurately reported in the press release. “To show conclusions of data is fundamental to the scientific process,” Haddad said.
Friday, April 15, 2011
InterMune ex-CEO Harkonen sentenced in Actimmune scandal
Former InterMune Inc. CEO Scott Harkonen was fined $20,000 and sentenced to six months of home confinement in connection to a misleading 2002 company press release about the drug Actimmune.
Harkonen was convicted of wire fraud in September 2009 after Brisbane-based InterMune distributed an Aug. 28, 2002, press release that claimed that Actimmune in a Phase III trial reduced deaths by 70 percent in patients with mild to moderate idiopathic pulmonary fibrosis.
Harkonen was convicted of wire fraud in September 2009 after Brisbane-based InterMune distributed an Aug. 28, 2002, press release that claimed that Actimmune in a Phase III trial reduced deaths by 70 percent in patients with mild to moderate idiopathic pulmonary fibrosis.
Thursday, March 3, 2011
InterMune IPF drug wins European approval
InterMune Inc. received approval from for Esbriet, its treatment for the fatal lung-scarring disease idiopathic pulmonary fibrosis
Wednesday, February 16, 2011
Drug rights sales pushes InterMune to $206M Q4 profit
The sale of rights to the drug danoprevir in October helped push Brisbane’s InterMune Inc. to a $206.1 million profit in the December quarter.
InterMune (NASDAQ: ITMN) brought in $175 million in that sale, and that, combined with about $57.3 million leftover from payments for a terminated agreement by giant F. Hoffman-La Roche Ltd., added up to the unusual profit. A year ago in the December quarter, InterMune lost $28.6 million.
Monday, January 10, 2011
Friday, January 7, 2011
Thursday, January 6, 2011
Friday, December 17, 2010
Subscribe to:
Posts (Atom)